Corindus Vascular Robotics Inc
Corindus Vascular Robotics — Investor Presentation (September 2016)
24 slides from Corindus Vascular Robotics's investor presentation, Sep 8, 2016
Slide 1: Precision Vascular Robotics
Precision Vascular Robotics Corindus Vascular Robotics (CVRS) September 2016
Slide 2: Forward-Looking Statements
THIS PRESENTATION CONTAINS “FORWARD - LOOKING STATEMENTS” (AS SUCH TERM IS DEFINED IN SECTION 27 A OF THE SECURITIES ACT OF 1933 , AS AMENDED, AND SECTION 21 E OF THE SECURITIES EXCHANGE ACT OF 1934 , AS AMENDED), AND INFORMATION RELATING TO THE COMPANY, THAT ARE BASED ON THE CURRENT BELIEFS OF, AND
Slide 3: Corindus Snapshot
Corindus Snapshot A leader in vascular robotics LARGE Market Opportunity with Long GROWTH Runway $4.5B 1 market opportunity in 2018 driven by over 2.5 million coronary and 3 million non - coronary procedures performed per year DIFFERENTIATED Technology ONLY FDA cleared robotic system for percutaneou
Slide 4: Traditional PCI vs CorPath Robotic PCI
Struggle to see angiography Assess Anatomy Close proximity ergonomic visualization Trial & error, wire spinning Navigate Precise ‘Point & Shoot’ predictability ‘Eyeball’ estimate Measure Anatomy Robotic - assisted sub - mm Measurement Manual adjustment Position Stent 1mm precise positioning Devices
Slide 5: New Leadership & Strengthening Team
New Leadership & Strengthening Team Building operational & clinical e xcellence Mark Toland President & CEO 20 Year Medical D evice V eteran J. Aaron Grantham, MD Chief Medical Officer Practicing Interventional Cardiologist Marty Leon, MD Executive Advisor Interventional Cardiology Thought Leader Ca
Slide 6: Corindus Strategic Imperatives
Corindus Strategic Imperatives Platform for growth Strengthen execution to increase adoption 1 Fuel physician community of support 2 Invest in technology roadmap 3 Expand into high growth disease segments 4 Drive global e xpansion 5 • US – focus on establishing deep relationships • China , Japan, Mi
Slide 7: CorPath System Platform Designed for Expansion
FFR ATHERECTOMY IVUS OCT Opportunities for integration Expanding clinical usage • Simple → Complex PCI • Radial PCI – FDA Cleared • Peripheral – FDA Cleared • Neuro – Exploratory • Structural Heart – Exploratory CorPath System Platform Designed for expansion 7 Open architecture • Device agnostic • A
Slide 8: Market Opportunity
1 Market opportunity assessment based on market research reports and Corindus estimate 2 Peripheral Vascular includes lower limb, carotid, renal, iliac and AAA (abdominal aortic aneurysm) procedures 3 Millennium Research Group Market Opportunity Large & growing worldwide market • $ 4.5B FY2018 marke
Slide 9: Expanding Market Opportunity
Peripheral (1.5M Procedures) Expanded indications and capabilities Expanding Market Opportunity Extensive runway Coronary Peripheral Neuro Structural March 2016 FDA 510(k) clearance for use in peripheral vascular Exploring the neurovascular and structural heart space with thought leaders to assess t
Slide 10: Growing Clinical Evidence
Growing Clinical Evidence Benefit to Physicians/Staff Benefit to Patient Benefit to Financials Benefit to Complex Cases 95% Reduction in Radiation Exposure Trial Showed Lower Patient Radiation Trial Showed Comparable Time R - PCI vs M - PCI Trial Showed Reduction in Stent Usage 10
Slide 11: Occupational hazards for interventionalists
• Brain tumors – Reported brain tumors are predominately left - sided amongst interventionalists 1 • Orthopedic injuries 2,4 – 60% incidence of spine issues after 21 years in practice – 42% incidence of spine problems, general population average rate - 2.3% – 33% miss work due to orthopedic issues •
Slide 12: Robotics Showed Lower Patient Radiation
Robotics Showed Lower Patient Radiation JIC published s ingle center trial, New York Presbyterian Procedural Characteristics Manual PCI N=80 Robotic PCI N=40 Percent Improvement Contrast Media Volume, ml 137 ± 62 121 ± 47 12% Fluoro Time, min 12.3 ± 7.6 10.1 ± 4.7 18% Radiation Dose, mGy 1665 ± 1026
Slide 13: Robotics Showed Reduction in Stent Use
Robotics Showed Reduction in Stent Use 8.3% stent reduction¹ ¹Campbell P.T., et al. The Impact of Precise Robotic Lesion Length Measurement on Stent Length Selection: Ramification For St ent Savings. Poster Presentation CRT 2015. 2 Campbell , P. T et al (2015), Interoperator and intraoperator (in)ac
Slide 14: Evidence of Success in Complex PCI
Evidence of Success in Complex PCI Methods: • 334 procedures – 108 R - PCI and 226 M - PCI • Patients in R - PCI group were more likely to have type B2 or C lesions (78% vs. 69%, p=0.02) Results: • R - PCI is safe and feasible in patients with complex coronary disease, 108 procedures; 91.7% technica
Slide 15: Evolution of Clinical Strategy
Evolution of Clinical Strategy Clinician driven deliverables through CMO feedback loop Strategic Shift Leverage Develop Scale • FDA clearance of NG2 (GRX) • Clinical Steering Committee • Technology deep dives with R&D • VP of Medical Affairs • Build clinical roadmap • Gen 3 development underway • Cl
Slide 16: Vascular Robotic Clinical Roadmap
Vascular Robotic Clinical Roadmap Demonstrating excellence in multiple lesion types and anatomies Product Evolution Robotic system capability Exploratory • Below the Knee • Ostial S tenting • Atherectomy • Drug Eluting Balloons • Left Main I ntervention • Complex PCI & CTO • Ostial Lesion • Absorb •
Slide 17: Addressing Healthcare Challenges
Addressing Healthcare Challenges Paradigm shift t owards the “How” not the “What” Safer Work Environment Improve Efficiency Reduce Cost Enhance Quality Expand Access To Care 17
Slide 18: Cardiovascular Robotics
Cardiovascular Robotics Foundation to t he f uture Advanced Device Manipulation Auto Navigation Algorithmic Decision Making Image/DX Integration Remote Telehealth 18
Slide 19: Technology Roadmap
Today 1 st Commercial • PCI fundamental • Wire and stent manipulation Robotic Adoption • Target 80% of cases • Procedure speed • Enhanced user experience • Algorithmic approach > 2020 Standard of Care • Target > 80% of cases • Remote teleprocedural control • Optimized to specific patient CorPath 200
Slide 20: Enhanced Commercial Approach
Enhanced Commercial Approach Nuances of market s uccess 20 • Long selling cycle • Multiple decision makers • Physician influence declining COMPLEXITY Approach • Sales model diversity • Training & development • KOL focus • Team approach • Workflow change (as much as procedural change) • Commitment =
Slide 21: Building Centers of Excellence
Building Centers of Excellence Driving strategic p lacements Team Approach (Physicians, techs, nurses and administration) Commitment to Building a Program Ongoing Training (Basic, intermediate and advanced) Adequate Procedural Volume (Support multiple users) Commercial Focus on Developing New Progra
Slide 22: Financial Snapshots
1 As of June 30, 2016 2 Outstanding principal balance Financial Snapshots Corindus Vascular Robotics Key Financial Metrics 1 Cash, Cash Equivalents and Marketable Securities $26.4 million Debt 2 $5.9 million Basic Shares Outstanding 119,049,519 Guidance 2016 Revenue $4 - $5 million 22
Slide 23: Strategic Objectives
Near - Term (2H 16) • Establish 6 - 9 robotic programs • Pursue co - development opportunities, add at least one additional collaboration Mid - Term (1H 17 – 1H 18) • Ramp robotic programs and utilization • Gen 2 system – launch ready in 1H 2017 • More than double 2016 revenues Long - Term (2H 18 –
Slide 24: About Corindus Vascular Robotics
About Corindus Vascular Robotics Corindus Vascular Robotics, Inc. is a global technology leader in robotic - assisted vascular interventions. The company's CorPath ® System is the first FDA - cleared medical device to bring robotic - assisted precision to percutaneous coronary intervention and perip
Corindus Vascular Robotics — Investor Presentation (September 2016) on 6ix